RT Journal Article
T1 Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
A1 Fanciulli, Chiara
A1 Berenguer, Juan
A1 Busca, Carmen
A1 Vivancos, María J
A1 Téllez, María J
A1 Domínguez, Lourdes
A1 Domingo, Pere
A1 Navarro, Jordi
A1 Santos, Jesús
A1 Iribarren, José A
A1 Morano, Luis
A1 Artero, Arturo
A1 Moreno, Javier
A1 Rivero-Román, Antonio
A1 Santos, Ignacio
A1 Giner, Livia
A1 Armiñanzas, Carlos
A1 Montero, Marta
A1 Manzardo, Christian
A1 Cifuentes, Carmen
A1 García, Coral
A1 Galindo, María J
A1 Ferrero, Oscar L
A1 Sanz, José
A1 de la Fuente, Belén
A1 Rodríguez, Carmen
A1 Gaspar, Gabriel
A1 Pérez, Laura
A1 Losa, Juan E
A1 Force, Luis
A1 Veloso, Sergio
A1 Martínez-Alfaro, Elisa
A1 Jarrín, Inmaculada
A1 De Miguel, Marta
A1 González Garcia, Juan
A1 GeSIDA 8514 Study Group, 
K1 HIV infection/*epidemiology
K1 coinfection/*epidemiology
K1 hepatitis C/drug therapy/*epidemiology
AB We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p  In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.
YR 2022
FD 2022-01-17
LK http://hdl.handle.net/10668/19960
UL http://hdl.handle.net/10668/19960
LA en
DS RISalud
RD Apr 9, 2025